Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

cbowers8171 Jan. 15 at 12:57 AM

$IMUX it's going to be a good year. There's no way any normal human with a half a brain could squander away this opportunity. Patience has and always will be the name of the game here.

0 · Reply

Mattjen Jan. 14 at 10:09 PM

$IMUX

0 · Reply

ErnieWorthing84 Jan. 14 at 8:24 PM

$IMUX Guess Chief Business Officer Patrick Walsh shit the bed again in San Fran.

1 · Reply

coujatrader Jan. 14 at 7:47 PM

$IMUX making wise choices today to spend more money on IMUX in hopes of a dream. Just like the casino yeah!

0 · Reply

Mattjen Jan. 14 at 5:54 PM

$IMUX i hope the 1:1s bear fruit!

1 · Reply

Lisamh76 Jan. 14 at 5:33 PM

$IMUX if i cashed out my position, the price of this stock would be .25 ps in 10 minutes, and i would lose to the tune of $22M

0 · Reply

TREBLALBERT Jan. 14 at 4:59 PM

$IMUX A close below $0.65 on strong volume is a bearish signal.

1 · Reply

Mattjen Jan. 14 at 4:45 PM

$IMUX

0 · Reply

Mattjen Jan. 14 at 4:40 PM

$IMUX

0 · Reply

Mattjen Jan. 14 at 4:32 PM

$IMUX let me see that big volume. Come on BD get us a deal!

0 · Reply

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Nov 26, 2025, 6:30 AM EST - 7 weeks ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 6:30 AM EST - 2 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 3 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 4 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 4 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 5 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 7 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 7 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 7 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 8 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 8 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 8 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 9 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 9 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 9 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 9 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 10 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 10 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 11 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 11 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 11 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

cbowers8171 Jan. 15 at 12:57 AM

$IMUX it's going to be a good year. There's no way any normal human with a half a brain could squander away this opportunity. Patience has and always will be the name of the game here.

0 · Reply

Mattjen Jan. 14 at 10:09 PM

$IMUX

0 · Reply

ErnieWorthing84 Jan. 14 at 8:24 PM

$IMUX Guess Chief Business Officer Patrick Walsh shit the bed again in San Fran.

1 · Reply

coujatrader Jan. 14 at 7:47 PM

$IMUX making wise choices today to spend more money on IMUX in hopes of a dream. Just like the casino yeah!

0 · Reply

Mattjen Jan. 14 at 5:54 PM

$IMUX i hope the 1:1s bear fruit!

1 · Reply

Lisamh76 Jan. 14 at 5:33 PM

$IMUX if i cashed out my position, the price of this stock would be .25 ps in 10 minutes, and i would lose to the tune of $22M

0 · Reply

TREBLALBERT Jan. 14 at 4:59 PM

$IMUX A close below $0.65 on strong volume is a bearish signal.

1 · Reply

Mattjen Jan. 14 at 4:45 PM

$IMUX

0 · Reply

Mattjen Jan. 14 at 4:40 PM

$IMUX

0 · Reply

Mattjen Jan. 14 at 4:32 PM

$IMUX let me see that big volume. Come on BD get us a deal!

0 · Reply

Tonsauce123 Jan. 14 at 4:13 PM

$IMUX guy below is hilarious, vittardio cares about us more than our mothers

0 · Reply

Jw242 Jan. 14 at 3:44 PM

$IMUX guy below is comical. Vittardio has done nothing to help shareholders

0 · Reply

emink1903 Jan. 14 at 11:14 AM

$IMUX I think the greatest achievement of the imux administration is getting these people hired by the company. This is perhaps as important as Phase 3

0 · Reply

emink1903 Jan. 14 at 11:11 AM

$IMUX The advantage for this team at imux is that they know their competitors very well. This will also increase the chances of success in any potential partnership or acquisition negotiations.

0 · Reply

emink1903 Jan. 14 at 11:09 AM

$IMUX I believe Simona Skerjanec and Jason Tardio are both incredibly experienced in their respective fields. It's highly unlikely they would participate in a project that would ultimately damage their reputation in the long run.

0 · Reply

Tradergrows Jan. 14 at 12:25 AM

$IMUX Dr. Vitt, you were right about BTK’s. We are ready to partner and are prepared for a bidding war. Sincerely, -Big Pharma https://www.biopharmadive.com/news/sanofi-multiple-sclerosis-btk-inhibitor-troubles/809443/ 🤞

1 · Reply

Cattitude Jan. 13 at 6:59 PM

$OCGN not taking away from here because I’m invested as well, but this $IMUX is also presenting and has massive potential! Give it a look 👀

1 · Reply

Jw242 Jan. 13 at 6:01 PM

$IMUX added 10k more today. RIP my man Bobby Weir!

0 · Reply

dgbio Jan. 13 at 11:44 AM

$TGTX should partner with $IMUX. Immunic needs cash, TG needs pipeline. This is the only P3 program in MS available for partnership and they can get cheaply into it.

0 · Reply

coujatrader Jan. 13 at 1:33 AM

$IMUX this is just fun loading up on dimes worth a penny

0 · Reply

Mattjen Jan. 12 at 9:51 PM

$IMUX link to slide presentation @ JPM 1:1 https://filecache.investorroom.com/mr5ir_immunic_therapeutics/734/20260111_Immunic_Company-Overview_January-2026.pdf

1 · Reply

Mattjen Jan. 12 at 9:01 PM

$IMUX 3 to 7 billion anticipated peak sales....

0 · Reply

Market Cap	79.57M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,784,600
Avg Vol	1,421,530
Day's Range	N/A - N/A
Shares Out	120.29M
Stochastic %K	81%
Beta	1.54
Analysts	Strong Sell
Price Target	$5.53